Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years: Phase II randomized controlled trial in Singapore

This was a multicenter, blinded, Phase II study (NCT00880893) conducted in Singapore. The primary objectives were to evaluate the safety of a tetravalent dengue vaccine (TDV) comprising four recombinant, live, attenuated viruses (CYD-TDV) and the dengue virus serotype-specific antibody responses bef...

Descripción completa

Detalles Bibliográficos
Autores principales: Sin Leo, Yee, Wilder-Smith, Annelies, Archuleta, Sophia, Shek, Lynette P., Chong, Chia Yin, Nam Leong, Hoe, Yong Low, Chian, Oh, May-Lin Helen, Bouckenooghe, Alain, Wartel, T. Anh, Crevat, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579907/
https://www.ncbi.nlm.nih.gov/pubmed/22894958
http://dx.doi.org/10.4161/hv.21224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579907/
https://www.ncbi.nlm.nih.gov/pubmed/22894958
http://dx.doi.org/10.4161/hv.21224

Ejemplares similares